Bio-Rad Laboratories, Inc. BIO.B Standard and Extended Product Warranty Accrual, Decrease for Payments

Standard and Extended Product Warranty Accrual, Decrease for Payments at other companies

GE HealthCare TechnologiesGEHC

——

Other financials

Income statement

See full

Revenue$592.1M+1.1%

Gross profit$309.4M+1.1%

Operating income$34.1M+43.9%

Net income-$527.1M-924%

EPS (diluted)-$19.55-954%

Balance sheet

See full

Cash & equivalents$509.0M-2.7%

Total debt$987.3M-28.4%

Total equity$6.9B+2.6%

Total assets$9.8B+2.8%

Cash flow

See full

Operating cash flow$108.1M-16.8%

CapEx$30.0M-12.8%

Free cash flow$78.1M-18.2%

Valuation

See full

Market cap$7.56B+10.3%

Enterprise value$8.04B+4.2%

P/E44.8×—

P/S2.9×+0.2×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin8.8%-3.1pp

Net margin6.5%+3.4pp

FCF margin13.8%-0.2pp

Returns & leverage

See full

Return on equity2.5%+1.3pp

Debt / equity0.1×-0.1×

Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProductWarrantyAccrualPayments.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s standard and extended product warranty accrual, decrease for payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s standard and extended product warranty accrual, decrease for payments?: Bio-Rad Laboratories, Inc. (BIO.B) reported standard and extended product warranty accrual, decrease for payments of $1.9M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s standard and extended product warranty accrual, decrease for payments changed year-over-year?: Bio-Rad Laboratories, Inc.'s standard and extended product warranty accrual, decrease for payments increased by 35.7% year-over-year, from $1.4M to $1.9M.